Different opinions on Oncothyreon

|By:, SA News Editor

Cantor Fitzgerald downgrades Oncothyreon (ONTY) from Buy to Hold citing valuation. Yesterday's close of $3.89 near its price target of $4.

Stifel maintains its Buy rating and raises its price target from $3 to $6 citing the potential long-term label expansion of ARRY-380.

The company expects to burn $30M - $33M next year. It has enough cash to fund operations for the next 12 months.

48 mutual funds have positions, down from 102 last year.